Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support

Hussam Suradi, Jeffrey Breall

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.

Original languageEnglish
Pages (from-to)437-440
Number of pages4
JournalTexas Heart Institute Journal
Volume38
Issue number4
StatePublished - 2011

Fingerprint

Myocarditis
Giant Cells
Equipment and Supplies
Heart Failure
Heart-Assist Devices
Cardiogenic Shock
Immunosuppressive Agents
Cardiac Arrhythmias
Therapeutics
Hemodynamics

Keywords

  • Autoimmune diseases/complications/drug therapy
  • Disease progression
  • Equipment design
  • Giant cells/drug effects/pathology
  • Heart failure/immunology/pathology
  • Heart-assist devices
  • Hemodynamics/physiology
  • Left
  • Myocarditis/diagnosis/epidemiology/ physiopathology/therapy
  • Treatment outcome
  • Ventricular dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{24f41733f5684930af25566970c6fbf1,
title = "Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support",
abstract = "Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.",
keywords = "Autoimmune diseases/complications/drug therapy, Disease progression, Equipment design, Giant cells/drug effects/pathology, Heart failure/immunology/pathology, Heart-assist devices, Hemodynamics/physiology, Left, Myocarditis/diagnosis/epidemiology/ physiopathology/therapy, Treatment outcome, Ventricular dysfunction",
author = "Hussam Suradi and Jeffrey Breall",
year = "2011",
language = "English",
volume = "38",
pages = "437--440",
journal = "Texas Heart Institute Journal",
issn = "0730-2347",
publisher = "Texas Heart Institute",
number = "4",

}

TY - JOUR

T1 - Successful use of the impella device in giant cell Myocarditis as a bridge to permanent left Ventricular mechanical support

AU - Suradi, Hussam

AU - Breall, Jeffrey

PY - 2011

Y1 - 2011

N2 - Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.

AB - Idiopathic giant cell myocarditis is a rare condition with a poor prognosis. Patients with giant cell myocarditis typically die of refractory ventricular arrhythmias or progressive congestive heart failure in about 3 months. The benefit of immunosuppressive therapy varies among patients with giant cell myocarditis, and no factors that would predict which patients will respond to therapy have been identified. Mechanical circulatory support devices, from intra-aortic balloon pumps to more permanent systems, have been used for ventricular support in cases of acute heart failure. Herein, we describe a case of giant cell myocarditis in a previously healthy 44-year-old woman who presented with cardiogenic shock. She was supported hemodynamically with the Impella Recover LP 2.5 left ventricular assist device until a permanent device could be surgically implanted. To our knowledge, this is the 1st reported case of the successful use of the Impella device for hemodynamic support in a patient with giant cell myocarditis until more definitive treatment could be instituted.

KW - Autoimmune diseases/complications/drug therapy

KW - Disease progression

KW - Equipment design

KW - Giant cells/drug effects/pathology

KW - Heart failure/immunology/pathology

KW - Heart-assist devices

KW - Hemodynamics/physiology

KW - Left

KW - Myocarditis/diagnosis/epidemiology/ physiopathology/therapy

KW - Treatment outcome

KW - Ventricular dysfunction

UR - http://www.scopus.com/inward/record.url?scp=80051710401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051710401&partnerID=8YFLogxK

M3 - Article

C2 - 21841879

AN - SCOPUS:80051710401

VL - 38

SP - 437

EP - 440

JO - Texas Heart Institute Journal

JF - Texas Heart Institute Journal

SN - 0730-2347

IS - 4

ER -